• p-tau Ser356, Alzheimer’s Pathology, and NUAK Inhibition

  2026-08-24

  Taylor and colleagues show that p-tau Ser356 increases with Alzheimer’s disease Braak stage and is broadly present in neurofibrillary tangles, with nanoscale evidence of synaptic colocalization. Their ex vivo experiments further reveal that NUAK inhibition produces distinct tau responses in postnatal mouse and adult human brain slice cultures, an important consideration for translational therapeutic studies.

• Hydroxychloroquine Sulfate Workflow Guide

  2026-08-24

  Hydroxychloroquine Sulfate (SKU B4874) provides an aqueous-compatible way to investigate autophagy pathway modulation and TLR7/9-dependent immune activation in autoimmune disease research. It is suited to freshly prepared, water-based workflows, but should not be selected for protocols requiring DMSO or ethanol solubility or prolonged storage of solutions.

• 7-Ethyl-10-hydroxycamptothecin Workflow Guide

  2026-08-23

  Build reproducible SN-38 experiments around topoisomerase I poisoning, apoptosis, and S-phase/G2 profiling in metastatic colon cancer models. Extend conventional cytotoxicity assays with the FUBP1–FUSE interaction assay to distinguish canonical DNA damage from transcriptional regulatory effects.

• Omeprazole A2845: Acid Secretion Workflow

  2026-08-22

  Omeprazole (SKU A2845) is a research-grade H+,K+-ATPase inhibitor for controlled gastric acid secretion experiments, antiulcer activity studies, and related assay development. This guide covers dossier-based handling and QC while defining boundaries: it is not intended for diagnostic, clinical, or medical use.

• SIS3: A Mechanistic Probe of TGF-β/SMAD3

  2026-08-22

  SIS3, a selective Smad3 inhibitor, offers a rigorous way to test TGF-β/SMAD3 dependency in cancer and fibrosis research. This article connects SIS3 pharmacology with super-enhancer-driven lung adenocarcinoma biology and translates that insight into practical assay decisions.

• BRD4770: G9a Histone Methyltransferase Inhibitor

  2026-08-21

  BRD4770 is a research-focused G9a histone methyltransferase inhibitor for connecting H3K9 methylation changes with senescence and cancer-cell growth phenotypes. This workflow-oriented guide covers formulation challenges, PANC-1 assays, mechanistic controls, and how to interpret findings alongside BRD4–RAC1 pathway research.

• Polybrene: From Transduction Aid to Translational Tool

  2026-08-20

  Polybrene (Hexadimethrine Bromide) is more than a viral delivery additive: it is a controllable experimental variable that can influence attachment, uptake, transfection performance, and assay interpretation. This thought-leadership perspective connects its delivery mechanism with recent findings on mitochondrial proteostasis and outlines a disciplined path from improved transduction to translationally credible conclusions.

• DCPS Links m7G Regulation to Diabetic Foot Ulcer Repair

  2026-08-20

  Xiao et al. identify the decapping scavenger enzyme DCPS as an m7G-related biomarker associated with diabetic foot ulcer pathology and epithelial repair. Integrating transcriptomic analysis with keratinocyte experiments, the study links reduced DCPS to impaired cell-cycle progression, proliferation, migration, and increased apoptosis, while also highlighting limitations that should be addressed before clinical translation.

• Jiao-tai-wan, Coptisine, and SIRT1 in PCOS

  2026-08-19

  A 2025 Phytomedicine study identifies mitochondrial cholesterol import as a mechanistic link between SIRT1 regulation and abnormal ovarian steroidogenesis in a DHEA-induced PCOS model. Its evidence suggests that Jiao-tai-wan and coptisine act partly by limiting SMURF2-mediated SIRT1 degradation, thereby altering StAR localization and theca-cell steroidogenic activity.

• Pol II Degradation and Transcription-Independent Cell Death

  2026-08-19

  The preprint argues that degradation of RNA polymerase II (Pol II) can activate cell death through a mechanism that is not simply a consequence of transcriptional collapse. Its main contribution is conceptual and experimental: it separates the effects of losing Pol II protein from the effects of losing transcription, providing a framework for interpreting regulated cell-death phenotypes after transcriptional perturbation.

• Angiotensin Peptides and SARS-CoV-2 Spike Binding

  2026-08-18

  Oliveira and colleagues showed that naturally occurring angiotensin fragments can increase SARS-CoV-2 spike-protein binding to host receptors, with especially strong effects in the spike–AXL interaction. The structure–activity findings extend renin-angiotensin system research into viral receptor biology while emphasizing that antibody-based binding results require validation in cellular and physiological models.

• P2RX1 and Mitochondrial Apoptosis in Ph+ ALL

  2026-08-18

  Li et al. identify P2RX1 as a mechanistic link between calcium dysregulation, CaMKII activation, PI3K/Akt suppression, and mitochondrial apoptosis in Philadelphia chromosome-positive acute lymphoblastic leukemia. The findings suggest that P2RX1 may influence both disease behavior and tyrosine kinase inhibitor response, while also defining experimentally testable readouts for cell-death studies.

• Capsaicin Workflows for TRPV1 and KDM1A Research

  2026-08-17

  Capsaicin enables a two-track research strategy: controlled TRPV1 ion channel activation in sensory models and mechanistic KDM1A/LSD1 inhibition in cancer studies. This workflow connects dose selection, electrophysiology, cell phenotyping, and troubleshooting while separating target-specific effects from solvent, desensitization, and cytotoxicity artifacts.

• Olsalazine Sodium Experimental Workflows

  2026-08-17

  Olsalazine Sodium supports complementary workflows spanning LTB4-driven inflammation, colorectal cancer tumor models, and xenobiotic transport assays. This guide emphasizes aqueous formulation, paired molecular and functional readouts, and troubleshooting strategies that prevent solubility or interpretation errors.

• Anlotinib Hydrochloride Angiogenesis Workflows

  2026-08-16

  Build more informative angiogenesis experiments with Anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor that connects endothelial migration, tube formation, receptor phosphorylation, and ERK readouts. This workflow emphasizes dose selection, orthogonal validation, and troubleshooting so anti-angiogenic effects can be separated from nonspecific cytotoxicity.

7979 records 1/532 page Next 12345 下5页 Last page